LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Strona główna・Stock List・Bio-Techne Corp

Bio-Techne Corp

Closed

Sector Healthcare

78.63 1.44

Buy Sell

Overview

Share price change

24h

Current

Min

77.61

Max

79.72

Key metrics
By Trading Economics
Income	22M 49M
Sales	303B 303B
P/E Sector Avg	50.64 79.786
EPS	0.48
Profit margin	0.016
EBITDA	8.2M 92M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+4.23 upside

Dividends
By Dow Jones
Next Earnings	7 sie 2024
Next Dividend date	30 sie 2024
Next Ex Dividend date	15 sie 2024

Market Stats
By TradingEconomics
Market Cap	1B 12B
Previous open	77.19
Previous close	78.63

News Sentiment

By Acuity

50%

123 / 369 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

77.77 / 80.515 Support & Resistance

Bio-Techne Corp Chart

Related News

25 lip 2024, 20:16 UTC

Earnings

Norfolk Southern Grows 2Q Profit, Seeks to Leave Behind Derailment Tailwinds

25 lip 2024, 22:57 UTC

Earnings

Minas Buenaventura 2Q Net $74.4M >BVN

25 lip 2024, 22:10 UTC

Earnings

Berkshire Is Quickly Cutting Its Stake in Bank of America. More Sales Could Be Coming. -- Barrons.com

25 lip 2024, 21:59 UTC

Market Talk

Earnings

Global Energy Roundup: Market Talk

25 lip 2024, 21:59 UTC

Market Talk

Earnings

Norfolk Southern Lowers Operating Ratio in 2Q, Shares Jump -- Market Talk

25 lip 2024, 21:51 UTC

Earnings

Update: Berkshire Is Quickly Cutting Its Stake in Bank of America. More Sales Could Be Coming. -- Barrons.com

25 lip 2024, 21:32 UTC

Acquisitions, Mergers, Takeovers

Noble: Special Meeting of Diamond Stockholders to Vote on Transaction Is Currently Scheduled for Aug 27 >NE

25 lip 2024, 21:32 UTC

Acquisitions, Mergers, Takeovers

Noble Corp and Diamond Offshore: Announce Expiration of Hart-Scott-Rodino Act Waiting Period and Provide Transaction Update

25 lip 2024, 21:18 UTC

Earnings

A.J. Gallagher Earnings Show Insurance Brokers Are Anything but Humdrum -- Barrons.com

25 lip 2024, 21:11 UTC

Peer Comparison

Price change

Bio-Techne Corp Forecast

Price Target

By TipRanks

4.23% upside

12 Months Forecast

Average 82 USD 4.23%

High 95 USD

Low 65 USD

Based on 8 Wall Street analysts offering 12 month price targets forBio-Techne Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Bio-Techne Corp - Dist in the past 3 months.

Technical Score

By Trading Central

77.77 / 80.515Support & Resistance

Bearish events outweigh bullish events.

All events are bullish.

The bullish and bearish events are balanced.

Sentiment

By Acuity

123 / 369 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Bio-Techne Corp

Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.